Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma
Chen Jiang,
Li-Yun Huang,
Ji-Hao Zhou,
Zhi-Ming Li,
Yu Wang,
Shuo Li,
Jian-Chang Fu,
Qi-Tao Huang,
Qin Yan,
Yu-Yuan Huang,
Min Zuo,
Shimin Hu,
Robert Peter Gale,
Yang Liang,
Jing-Ping Yun,
Yu-Hua Huang
Affiliations
Chen Jiang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Li-Yun Huang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Ji-Hao Zhou
Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, P.R. China
Zhi-Ming Li
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Yu Wang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Shuo Li
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Jian-Chang Fu
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Qi-Tao Huang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Qin Yan
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
Yu-Yuan Huang
Department of Pathology, Dongguan Children’s Hospital, Dongguan, Guangdong, P.R. China
Min Zuo
Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, P.R. China
Shimin Hu
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Robert Peter Gale
Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK
Yang Liang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Corresponding author
Jing-Ping Yun
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Corresponding author
Yu-Hua Huang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China; Corresponding author
Summary: The role of Epstein-Barr virus (EBV) in lymphoma cells of nodular sclerosis classic Hodgkin lymphoma (NScHL) is controversial. Our aim was to explore this and establish a clinically feasible model for risk stratification. We interrogated data from 542 consecutive subjects with NScHL receiving ABVD therapy and demonstrated EBV-infection in their lymphoma cells with EBV-encoded small RNAs (EBERs) in situ hybridization. Subjects were divided into training and validation datasets. As data from the training dataset suggested EBERs-positivity was the only independent prognostic factor for both progression-free survival (PFS) and overall survival (OS), we developed corresponding prognostic models based on it. Our models showed excellent performance in both training and validation cohort. These data indicate the close association of EBV infection and the outcomes of persons with NScHL receiving ABVD. Additionally, our newly developed models should help physicians estimate prognosis and select individualized therapy.
